Inovio Pharmaceuticals Inc [INO] stock prices are up 6.52% to $13.88 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The INO shares have gain 26.41% over the last week, with a monthly amount glided 64.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine. In a post published today on Yahoo Finance, INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
From an analyst’s perspective:
Inovio Pharmaceuticals Inc [NASDAQ: INO] stock has seen the most recent analyst activity on January 25, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $4 for it. Previously, Maxim Group downgraded its rating to Hold on November 09, 2022. On November 01, 2022, downgrade downgraded it’s rating to Underperform but maintained its price target of $2 on the stock. Oppenheimer downgraded its rating to a Perform. BofA Securities upgraded its rating to Neutral for this stock on January 21, 2022, and upped its price target to $10.
The stock price of Inovio Pharmaceuticals Inc [INO] has been fluctuating between $3.89 and $13.32 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Inovio Pharmaceuticals Inc [NASDAQ: INO] shares were valued at $13.88 at the most recent close of the market. An investor can expect a potential drop of -71.18% based on the average INO price forecast.
Analyzing the INO fundamentals
The Inovio Pharmaceuticals Inc [NASDAQ:INO] reported sales of 0.83M for trailing twelve months, representing a drop of -17.66%. Gross Profit Margin for this corporation currently stands at -38.1% with Operating Profit Margin at -173.0%, Pretax Profit Margin comes in at -162.4%, and Net Profit Margin reading is 3430.55%. To continue investigating profitability, this company’s Return on Assets is posted at 16.5, Equity is 18.29 and Total Capital is -1.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.02 points at the first support level, and at 12.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.71, and for the 2nd resistance point, it is at 15.55.
Inovio Pharmaceuticals Inc [INO] reported earnings per share of -$1.12 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of $0.15 and a surprise factor of 11.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.56 per share as compared to estimates of -$1.52 per share, a difference of -$0.04 representing a surprise of -2.60%.
Ratios To Look Out For
It’s worth pointing out that Inovio Pharmaceuticals Inc [NASDAQ:INO]’s Current Ratio is 3.60. On the other hand, the Quick Ratio is 3.60, and the Cash Ratio is 0.34. Considering the valuation of this stock, the price to sales ratio is 390.81, the price to book ratio is 2.70.
Transactions by insiders
Recent insider trading involved Zoth Lota S., Director, that happened on Jun 05 ’23 when 5700.0 shares were sold.
